Tumor immune microenvironment (TIME) plays an important role in metastasis and 28 immunotherapy. However, it has been not much known how to classify TIMEs and how TIMEs are 29 genetically regulated. Here we showed that tumors were classified into poor subtypes which had significant differences in clinical outcomes, abundances of tumor-infiltrating 31 lymphocytes (TILs), the degree of key immune programs' activation, and immunotherapy response 32 across 13 common cancer types (n= ~6,000). Furthermore, TIME-intermediate/-poor patients had 33 significantly more inherited genetic defects (i.e., functional germline variants) in natural killer (NK) 34 cells, antigen processing and presentation (APP) and Wnt signaling pathways than TIME-rich patients, 35 and so did cancer patients than non-cancer individuals (n=4,500). These results suggested that 36 individuals who had more inherited defects in NK cells, APP and Wnt pathways had a higher risk 37 of developing cancers. Moreover, in the 13 common cancers the number of inheritably defected 38 genes of NK cells was significantly negative-correlated with patients' survival, TILs' abundance in 39
Introduction 50 whole-exome sequences of germline genomes) of TCGA (The Cancer Genome Atlas) cancer patients 81 (n=~6,000) representing 13 common cancer types, and a non-cancer cohort (n=4,500) to show that 82 tumors were classified into three universally distinct TIME subtypes across the 13 common cancer 83 types. They were different in prognosis, TILs' abundance and degree of immune programs' activation, 84 regardless of cancer type. Inherited defects of NK cells, antigen processing and presentation (APP) and 85 Wnt pathways in patients' germline genomes modulated TIME subtypes and ICT response. 86 Importantly, we showed that inherited defects in NK cells alone were sufficient to regulate TILs' 87 abundance in TIMEs, clinical outcomes and immunotherapy response. Further, individuals who have 88 inherited defects in NK cells, APP and Wnt pathways bear high-risk of developing cancers. 89
Results 90
Three universal TIME subtypes across 13 common cancers 91
To classify tumors into TIME subtypes, we applied the unsupervised clustering of gene expression 92 data (i.e., melanoma data from TCGA) based on a set of genome-wide CRISPR-Cas9 screen-93 determined essential genes (i.e., ICT essential genes, n=1,294) from a previous study ( 12 ) and other 94 known tumor immune-related genes ( 13, 14 ) (see Methods). We found that melanoma tumors were 95 classified into three TIME subtypes (Fig 1a) . Similarly, the three TIME subtypes were repeatedly 96 obtained in the 13 common cancer types ( Supplementary Fig 1) : bladder urothelial carcinoma (BLCA), 97 breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical 98 adenocarcinoma (CESC), colon adenocarcinoma (COAD), head and neck squamous cell carcinoma 99 (HNSC), kidney renal clear cell carcinoma (KIRC), lower grade glioma (LGG), lung adenocarcinoma 100 (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PRAD), skin cutaneous 101 Melanoma (SKCM), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA) and uterine corpus 102 endometrial carcinoma (UCEC). These results suggested that TIME subtypes were much simpler than 103 tumor molecular subtypes, each of which was unique and couldn't be shared by any two cancer types. 104
Thus, the universal TIME subtypes provided a means to identify subtypes' unifying features and to 105 understand the underlying common molecular mechanisms of each TIME subtype. 106 107 To discover the common features and critical differences which defined the 3 distinct TIME subtypes, 108 we compared their gene expression profiles, TILs' abundance in TIMEs and clinical outcomes. The 109 abundance of TILs in TIMEs were significantly decreased from TIME-rich ('immune-hot' tumors), -110 intermediate ('immune-cold' tumors) to TIME-poor subtype ('immune-desert' tumors) (Fig 1b, 111 Supplementary Table 1 ). It has been known that TILs are associated with tumor prognosis, thus we 112 hypothesized that clinical outcomes could be different between TIME subtypes. In fact, both TIME-113 poor and -intermediate tumors had significantly poorer clinical outcomes than TIME-rich tumors (Fig  114   1c ), however, patient survival differences were not significant between TIME-poor and -intermediate 115 tumors. Pathway enrichment analysis of the significantly modulated genes between subtypes showed 116 that the degree of the activated (i.e., represented by gene expression of each pathway or program) 117 immune programs such as APP, NK cell-mediated cytotoxicity, T cell receptor singling pathways were 118 significantly decreased from TIME-rich, -intermediate to -poor subtype (Fig 1d and Supplementary Fig  119   2 ). These results suggested that TIME-poor and -intermediate tumors had a lower degree of activated 120 immune programs so that they could have a better chance to escape immunosurveillance. For example, 121 APP is an immunological process that prepares and presents antigens to T cells. NK effector and T cell 122 receptor signaling pathways function as tumor cell killing. Therefore, lower activity of APP, NK cells 123 and T cell receptor singling allow tumor cells to have fewer immune constraints. These results were 124 repeatedly observed across the 13 common cancer types, suggesting that the TIME subtypes are not 125 only universal subtypes across cancer types but also share common cellular and clinical features. 126
127
In general, TIME-rich, -intermediate and -poor tumors represent 25.35%, 32.94%, and 41.70% of the 128 tumors, respectively, depending on cancer types ( Supplementary Table 2 ). These results indicated that 129 TIME-rich patients represent only a small fraction of tumors, and more than 70% of the tumors are 130 either TIME-poor or -intermediate tumors, most of which are known to non-respond to ICT. These 131 results explain why only 10-40% of tumors (i.e., depending on the cancer type) respond to ICT. 132
Inherited defects in NK cells shape TIME subtypes and clinical outcomes 133
The discovery of the universal TIME subtypes across the 13 common cancer types triggered us to 134 hypothesize that the TIME subtypes could be modulated by common genetic regulators. We previously 135
proposed that pre-existing inherited variants in germline genomes of cancer patients could play an 136 important role in shaping somatic mutations, CNVs and oncogenic pathways in their paired tumor 137 genomes ( 15 ). Furthermore, we have shown that inheritably functional variants of breast cancer patients 138 significantly predicted tumor recurrence ( 16, 17 ), and the risk for breast, brain and other cancers ( 18 ). 139
Moreover, inheritably functional variants of patients could be used to predict key somatic-mutated 140 genes in their paired tumor genomes (Zaman et al., unpublished data To answer this question, we compared the functional germline variants (termed as inherited defects 145 here, see Methods) of the patients between TIME subtypes and showed that genetic makeups of the 146 patients were significantly different between them ( Supplementary Fig 3) : TIME-poor/-intermediate 147 and TIME-rich patients had significantly differentially inherited genetic defects. Further pathway 148 enrichment analysis showed that more than 30% of the defected or modulated pathways were 149 associated with NK cell deficient phenotypes, NK cell-associated virus infections, and the NK cell-150 mediated cytotoxicity pathway (Fig 2a, Supplementary Fig 4) . For example, among the significantly 151 differential pathways and phenotypes, 7 of them were known NKD (NK cell deficiency) phenotypes 152 ( 19, 20, 21 ) such as Epstein-Barr virus (EBV) infection, Herpes simplex infection, Leishmaniasis, 153 Rheumatoid arthritis, Type I diabetes mellitus, long-term depression and viral myocarditis, while 7 of 154 them were NK cell-related virus infections such as Graft-versus-host disease, HTLV-I infection, 155
Hepatitis B and C, Influenza A, Asthma and IBD (Fig 1d, 2a , and 2b). These results strongly suggested 156 that TIME-poor/-intermediate patients might have more inherited defects in their NK cells than TIME-157 rich patients. 158 159 NK cells are the 'first-line immune cells' which enable to quickly detect and attack tumor cells and 160 viruses. NK cells are able to control tumorigenesis by accurately regulating the distinct germline 161 encoded inhibitory and activating NK cell surface receptors. In general, an excess of activating over 162 inhibitory signals triggers the production and release of effector molecules, which can lead to the death 163 of the infected or transformed cancer cell ( 22 ). Thus, to further explore the association between NK cell 164 inherited defects with cancer progression and metastasis, we compiled a comprehensive set of NK cell 165 genes including NK cell receptors and ligands, genes in NK cell signaling pathways (i.e., KEGG NK 166 cell-mediated cytotoxicity pathway ( 23, 24, 25 ), and then conducted Fisher's tests to identify genes which 167 had significantly differential frequencies between TIME-rich group and TIME-poor/-intermediate 168 group. For a given cancer type, we found 15-20 defected NK cell genes which had significantly higher 169 frequencies in TIME-poor/-intermediate group than TIME-rich group (FDR-corrected p <0.25). The 170 gene list for each cancer type was different, which could be associated with the diversity of tissue-171 resident NK cells, although many of the significantly defected NK cell genes of the 13 cancer types 172 were shared. In total there were 103 such genes (i.e., termed as NK-genes here), 70 of which appeared 173 in at least two cancer types. Among the 70 NK-genes, 37.2%, 25.8%, 24.3%, and 12.7% are known 174 NKD genes ( 19, 20, 21 ), NK cell receptors and ligands, NK cell singling genes but also expressed in cell 175 signaling in T or other immune cells (i.e., mainly innate immune cells, termed as 'global immune cell 176 genes' here) and universal genes (i.e., expressed in many cell types), respectively ( Supplementary  177   Tables 3 and 4) . 178 179 We further asked if inherited defected NK-genes were correlated with clinical outcomes. To answer 180 this question, for each cancer type, we top-to-bottom ranked the patients based on the number of 181 inheritably defected NK-genes. We defined top 40% and bottom 40% of the ranked patients as high-182
and low-NK cell defected groups, respectively, to conduct survival analysis. In 10 of the 12 cancer 183 types (i.e., no survival data were available for THCA) except LGG and KIRC, the high-NK cell 184 defected group had significantly shorter survival than the low-NK cell defected group (Fig 3a) . 185
Similar results were obtained when using top 30% and bottom 30% of the ranked patients as high-186
and low-NK cell defected groups, respectively. These results suggested that NK cells inherited 187 defects could play an important role in tumor recurrence and overall survival in most of the cancer 188 types. Given the fact that TILs' abundance was different between TIMEs, we hypothesized that NK 189 cell defected gene number could be negatively correlated with the TILs' abundance in TIMEs. 190 Indeed, it was true that for all the 13 cancer types (Fig 3b, Supplementary Fig 5) , the abundance of including tumor cells. Therefore, NKD genes and NK receptors/ligands are more NK cell-specific (i.e., 201 representing 63% of the NK-genes, termed as NK-specific-genes here), while the global immune cell 202 genes (i.e., representing 24.3% of the NK-genes) and the universal genes (i.e., representing 12.7% of 203 the NK-genes) are expressed in multiple immune cells and non-immune cell types, respectively. Thus, 204
we raised a question whether the correlations observed in universal genes, there were not any correlation as shown in Fig 3a and 3b, suggesting that inherited 207 defects in the universal genes alone are insufficient to modulate either TILs in TIMEs or clinical 208 outcomes. Next, we re-did the same analyses by combining of the universal genes and the global immune cell genes (i.e., representing 37% of the NK-genes, termed as NK-immune-universal-genes 210 here) and the NK-specific-genes, respectively. For the NK-immune-universal-genes, correlations, as 211 shown in Fig 3a ( i.e., survival), were not observed, on the other hand, for the NK-specific-genes, such 212 correlations were reproduced across the 10 cancer types. These results suggested that the NK-specific-213 genes are sufficient to shape clinical outcomes, but the NK-immune-universal-genes were not. 214
215
Similarly, significantly negative correlations between TILs' abundance in TIMEs and the number of 216 the inheritably defected NK-specific-genes were reproduced in 10 cancer types including BLCA, 217 BRCA, KIRC, LAUD, LUSC, THCA, UCEC, HNSC, LGG, and SKCM (Fig 3b, Supplementary Fig  218   5 ). In particular, the correlations derived from the NK-specific-genes were much stronger than those 219 derived from the NK-genes in 7 cancer types (i.e., BLCA, BRCA, KIRC, LAUD, LUSC, THCA and 220 UCEC, Fig 3b, Supplementary Fig 5) . On the other hand, weaker negative correlations (i.e., correlation 221 co-efficiencies were 2-10 times less than those derived from the NK-genes) and weaker statistical 222 significances (i.e., p values in the range of 0.01-0.05) were observed for some immune cells in some 223 cancer types when using the NK-immune-universal-genes (Fig 3b, Supplementary Fig 5) . These results 224 suggested that inherited defects of the NK-specific-genes are sufficient to impair communications 225 between NK cells and other immune cells and then block TILs' recruitment into TIMEs. Of note, in 226 COAD, STAD, and PRAD, both NK-specific-genes and NK-immune-universal-genes did not 227 reproduce the negative correlation (i.e., for TILs in TIMEs) derived from the NK-genes. PRAD has 228 dense stroma ( 27 ) which could need the whole NK gene set (i.e., NK-genes) for TILs' recruitment. NK 229 cells surrounding both COAD and STAD are directly interacting with environmental factors such as 230 microbiome, food, drinks, and others so that NK cells associated with both COAD (colon cancer) and 231 STAD (gastric cancer) are much more complex. These data highlighted that inherited defected in NK 232 cells are one of the key genetic factors in shaping TIME subtypes, TILs' abundances and clinical 233 outcomes. 234 235 Based on these insights, we hypothesized that NK cell was a critical factor for recruiting immune 236 troops into TIMEs. This hypothesis is partially supported by two recent studies which had no idea 237 about NK cell inherited defects ( 27, 28 ), but showing that depletion of NK cells resulted in failed 238 recruitment of CD8+ T cells to the tumor microenvironment in melanoma mice. They further showed 239 that NK cells recruited CD103+ DC, which in turn were required for the recruitment of effector T 240 cells. Our results here suggested that NK cells could be able to recruit not only CD103+ DC (cDC) and 241 CD8+ T cells but also 30 other immune cells. Because NK cells act as first responders to detect and 242 kill cancer cells, it is reasonable to believe that NK cells could sequentially recruit many other 243 immune cells including CD103+ DC and T cells into the tumor microenvironment. Thus, NK cells 244 could recruit a whole immune troop but not only one or two immune cell types into TIMEs. 245
246
This insight provides a potential opportunity that adoptive cell transfer of NK cells from healthy donors 247 could convert a TIME-poor tumor into a TIME-rich tumor. Adoptive NK cell was safe and does not 248 cause a graft-versus-host disease attack on the recipients. Thus, we hypothesized that adoptive NK cell 249 transfer of healthy donors (i.e., allogeneic) to a patient could have better clinical outcomes than the 250 adoptive transfer of NK cells from the patients themselves (i.e., allogeneic) because cancer patients' 251 own NK cells are defected and don't function very effectively. This hypothesis is supported by a recent 252 clinical trial showing that allogenic adoptive NK cell transfer was much better than autogenic NK cell 253 immunotherapy for breast cancer outcomes ( 29 ). TIME-rich tumors are more suitable to conduct 254 immunotherapy than TIME-poor tumors, while TIME-rich tumors can gain significantly more survival 255 benefit than TIME-poor tumors for neoadjuvant chemotherapy as well. For example, a meta-analysis of 256 13 studies showed that higher abundance of TILs in pre-treatment tumor biopsy was correlated with 257 better pathological complete response rates to neoadjuvant chemotherapy ( 30, 31, 32, 33, 34 ). Therefore, it is 258 a great interest to improve patient outcomes by applying adoptive transfer of healthy, functional NK 259 cells to convert TIME-poor tumors into TIME-rich tumors which could be in turn treated with 260 chemotherapy or immunotherapy. A recent clinical trial partially supported this hypothesis: adoptive 261 transfer of NK cells in combination with chemotherapy in stage IV colon cancers significantly 262 prevented recurrence and prolonged survival than chemotherapy alone. Most importantly, they found 263 that poorly differentiated colon cancers were more susceptible to adoptive NK cell transfer than well-264 differentiated ones ( 35 ). Poorly and well-differentiated cancers are shorter and longer survival patients, 265 respectively, which are corresponding to TIME-rich and -poor tumors, respectively. Therefore, these 266 results agree with our above hypothesis. Another study also supported this hypothesis: the combination 267 therapy of anti-PD-1 antibodies and activated autologous NK cells significantly delayed tumor 268 progression in glioma-bearing animals as compared to the monotherapy regimens of anti-PD-1 or 269 stimulated NK cells alone (P<0.001)( 36 ). patients. APP is a biological process which presents antigens to T cells, functional defects in APP could 275 lead tumor cells to escape T cell surveillance. However, careful analyses showed that APP pathway 276 genetic defects were not significantly associated with clinical outcomes and TILs' abundance. These 277 results suggested that APP pathway defects alone were not sufficient to shape either clinical outcomes 278 or TIME subtypes. In addition, it has been shown that activated Wnt signaling pathway in tumors 279 excluded the recruitment of T cells into TIMEs ( 37 ). Furthermore, somatic mutations of the Wnt 280 pathway in tumors could activate the pathway to prevent T cells to be recruited into TIMEs ( 38 ). Here 281 we showed that in most of the cancer types the number of inherited defects in Wnt pathway in germline 282 genomes had a positive correlation with the gene expression of the Wnt pathway (i.e., pathway 283 activation) in their paired tumors, suggesting that a positive correlation between inherited defects in the 284 Wnt pathway and activation of the pathway, which is similar to the somatic mutations in genes of the 285 pathway. 286
287
The number of the inheritably defected genes in the Wnt pathway had weakly negative correlations 288 (i.e., with marginally significant p values in the range of 0.02-0.05) with clinical outcomes in 8 cancer 289 types (i.e., BLCA, BCRA, HNSC, LAUD, LUSC, PRAD, STAD and UCEC) and no such correlation 290 with other cancer types ( Supplementary Fig 6) . Similarly, Wnt pathway inheritably defected gene 291 number had negative correlations with the abundance of TILs in TIMEs ( Supplementary Fig 7) in eight 292 cancer types (i.e., HNSC, KIRC, LGG, LUAD, LUSC, SKCM, STAD and THCA), however, the 293 correlations were weaker (i.e., in terms of correlation co-efficiencies and correlation significance 294 represented by p values) than those derived from NK cells. These results suggested that inheritably 295 defected in Wnt pathway could shape TILs' recruitment in some cancer types, and the influences were 296 much weaker than NK cells. Next, we asked if inheritably defects of the Wnt pathway and NK cells 297 worked in a synergy manner. To answer this question, we conducted the correlation analysis using the 298 genes combined from the NK cells and the Wnt pathway and showed that negative correlations 299 between the inheritably defected gene number and the TILs' abundance in TIMEs remained in eight 300 cancers but much weaker than the correlations derived from either NK cells or Wnt pathway alone. 301
These results suggested that both NK cells and Wnt pathway were parallel and complementary 302 modulators to shape TILs recruitment, implying that to reverse immune exclusion in TIMEs, Wnt 303 signaling inhibitors could be better than adoptive NK cell transfer in some tumors but not most of the 304 tumors. 305
306
Together with the discovery that TIME-rich tumors have significantly longer survival than TIME-307 poor/-intermediate patients, we concluded that inherited defects in NK cells and Wnt pathways were associated with metastasis and clinical outcomes. These results highlighted that metastasis is affected 309 by inherited defects and is not a random process. Similarly, significantly more inherited defects in NK 310 cells, APP and Wnt pathways were observed between non-cancer individuals and cancer patients in the 311 13 common cancer types ( Supplementary Fig 8) . They were even more significant between TIME-312 poor/-intermediate patients and non-cancer individuals (Fig 2b and Supplementary Fig 9) . These results 313 suggested that individuals who bear inherited defects in NK cells, APP and Wnt pathways have a 314 higher risk to get cancer. This hypothesis is indirectly supported by a study showing that individuals 315 with lower NK cytotoxic activity in peripheral blood had a higher incidence of cancer (n=3,500 with 316
11-year follow-up) 39 ). Similarly, previous studies showed that impaired NK cell activity was found in 317 family members of patients with different types of cancer ( 40, 41, 42 ). Importantly, such inherited defects 318 in NK cells, APP and Wnt pathways were repeatedly observed between non-cancer and cancer 319 individuals (Fig 2b, Supplementary Fig 9) , between TIME-rich and TIME-intermediate/-poor patients 320 (Fig 2a, Supplementary Fig 4, Fig 1d) , suggesting that these individuals were highly selected for 321 tumorigenesis and metastasis. The immune programs (defects in NK cells, APP and Wnt pathways) are 322 carried from germline genomes to their paired tumors. In fact, the number of inherited defects in the 323 NK cells, APP and Wnt pathways was gradually increased from the non-cancer cohort, TIME-rich, -324 intermediate to -poor subtypes, suggesting that inherited defects in the NK cells, APP and Wnt 325 pathways have a profound impact on cancer risk, TIME subtypes and clinical outcomes. These insights 326 provided a potential opportunity to identify high-risk cancer subpopulation based on the inherited 327 defects in NK cells, APP and Wnt pathways, further, adoptive NK cell transfer from healthy donors to 328 high-risk individuals could postpone or prevent cancer development. This hypothesis is partially 329 supported by a study showing that NK cell depletion in melanoma mice resulted in substantial 330 metastasis, but the adoptive transfer of NK cells protects NK cell-deficient mice from tumor 331 establishment ( 43 ). 332
333
In addition, as shown in Fig 2b, Type I diabetes and long-term depression phenotypes were linked to 334 some cancers, suggesting that they were genetic diseases as well. Diabetes and obesity have been 335 shown to be a risk factor for some cancers, for example, a meta-analysis of 121 cohorts including 20 336 million individuals and one million events confirmed that diabetes is a risk factor for all-site cancer 337 ( 44 ), while obesity can increase cancer incidences of 13 cancer types ( 45 ). A 24-year follow-up study 338 showed that depression increases the risk of cancer ( 46 ), Moreover, a meta-analysis of 16 studies 339 (n=163,000) showed that cancer patients with anxiety and depression had a greater risk of dying from 340 all types of cancer ( 47 ). Impairing of the NK cell function is one of the common factors behind these links. For example, obesity has been known to impair NK cell function and then lead to an increased 342 risk for severe infections and several cancer types ( 48, 49 ), while chronic family stress is consistently 343 associated with decreases in NK cell cytotoxicity ( 50 ). These results indicated that NK function 344 impaired by either genetic defects or regulatory factors such as depression, obesity and diabetes could 345 increase cancer incidence. were assigned into TIME-rich and TIME-intermediate/-poor group, respectively. In contrast, 31% and 359 69% of the ICT non-responding gastric tumors were assigned into TIME-rich and TIME-intermediate/-360 poor group, respectively. Not surprisingly, these results indicated that TIME-rich patients were 361 enriched with ICT responders. Pathway enrichment analysis of tumor gene expression profiles showed 362 that TIME-rich non-responders had significantly higher gene expression in Wnt pathway (FDR-363 corrected p=5.3x10 -12 and 4.0x10 -5 for melanoma and gastric tumors, respectively) than TIME-rich 364 non-responders, suggesting that using of Wnt inhibitors could improve ICT treatment for TIME-rich Tumor molecular subtypes could inform not only prognosis but also treatment. Here we showed that 378
TIMEs can be classified into three universal subtypes across 13 common cancer types. Different from 379 previous observations of the complex tumor molecular subtypes, each of which often has its own 380 unique features, the universal TIME subtypes were commonly shared by multiple cancer types, 381 providing a framework to get better insight into the unifying features of each TIME subtype and the 382 differences between the distinct TIME subtypes, and then understand why some tumors respond to 383 immunotherapy and some don't. Furthermore, this framework allows exploring genetic factors to 384 regulate TIMEs and could help in identifying new druggable targets. Regardless of cancer types, TIME 385 subtypes have unifying features: (1) TIME-rich patients have significantly longer survival than other 386 TIME subtypes, because (2) the abundance of the TILs in TIME-rich, -intermediate and -poor tumors is 387 gradually decreased. These features recaptured the known immune-hot, -cold and -desert tumors 388 described previously based on immunohistochemistry ( 53, 54 ). It has been well-known that a lower 389 abundance of TILs in TIMEs is associated with more cancer recurrence and shorter survival ( 55, 56 ). (3) 390 signaling pathways associated with key immune programs such as APP, NK, and T cell signaling were 391 more highly activated in TIME-rich tumors than TIME-intermediate/-poor tumors. The degree of the 392 activated immune programs (i.e., represented by the expression levels of the pathway genes) was 393 gradually decreased from TIME-rich, -intermediate to -poor tumors. Lower level expression of the 394 genes in these immune-programs and pathways will allow tumors to escape from immune attack. (4) 395 finally, ICT-responders were more enriched in TIME-rich tumors. 396 397
Cancer is an NK cell deficient disease 398
The hypothesis of cancer immunosurveillance suggests that tumor cell transformation occurs 399 frequently, but is under constant control by the immune system. The immune system is able to identify 400 transformed cells that have escaped cell-intrinsic tumor-suppressor mechanisms and eliminate them 401 before they can establish malignancy ( 57 ). Thus, if the individuals are genetically immunodeficient, 402 they could have a markedly increased incidence of cancer. In general, NK cells have a large repertoire 403 of germline-encoded inhibitory and activating receptors to sense 'danger' in the cell surfaces. The 404 germline-encoded receptors which recognize ligands associated with viral infection or cancer cell 405 transformation ( 10 ). Genetic defects in NK-genes including NK cell receptors and NKDs could impair 406 provided a clearer view of the spectrum of malignancies associated with impaired NK cells and showed 408 that inherited defects affecting NK cell functions were sufficient to accomplish cancer 409 immunosurveillance of the immune system. 410 411 Among highly related pathways (i.e., NK cells, APP and Wnt pathways) examined, only NK-genes' 412 defects were correlated with both survival and the abundance of TILs in TIMEs. Most importantly, in 413 10 out of the 12 common cancers (i.e., no survival data were available for THCA), defects of the NK-414 specific-genes (i.e., NKDs + NK cell receptors) alone were sufficient to establish these correlations 415 (i.e., survival and TILs' abundance). Traditionally, the hypothesis of cancer immunosurveillance 416 mainly focuses on T cell or other immune cells for their cell-killing function. Here we demonstrated 417 that to implement cancer immunosurveillance, NK cells could play a critical role in communicating 418 with many immune cells to recruit the whole immune troops into the cancer-transformed cell or 419
TIMEs. Specifically, our results suggested that NK cells could have two functions for controlling tumor 420 progression and metastasis: (1) cancer cell killing (2) recruiting immune troops into TIMEs. Here we 421 proposed a working model for NK cell-based immunosurveillance: NK cells are the first to arrive in the 422 tumor microenvironment and recruit CD103+ DC through the secretion of chemokines. TIL-DCs then 423 recruit effector T cells. Activated NK cells produce numerous cytokines, communicate with other 30 424 immune cells, and then recruiting the immune troops into the cancer cell or TIMEs. Anti-tumor 425 and anti-metastasis activity (i.e., survival differences between TIME subtypes) is thus the result of the 426 collaboration of distinct innate and adaptive immune cell types. Thus, inheritably defected NK-genes 427 could impair NK cell function and then block to recruit the immune troops to the cancer cell or into 428
TIMEs to conduct the anti-tumor activity. Thus, we proposed that cancer is largely a disease of NK cell 429 deficiencies. This working model unraveled the cellular and molecular determinants (i.e., NK cells) of 430 multiple immune cell recruitment to and retention in solid tumors' TIMEs. Thus, allogeneic adoptive 431 NK cell therapy (i.e., collecting healthy NK cells which have no inherited defects from donors and 432 infusing them into the patient) could convert immunotherapy-resistant, TIME-poor tumors into 433 ICT/CAR-T-sensitive, TIME-rich tumors. This NK cell therapy could be a universal approach which is 434 independent of cancer types. Given the fact that more than 70% of the cancer patients are immune-cold 435 and -desert subtypes, successfully validating of this hypothesis will be a crucial step toward improving 436 the existing immunotherapies. 437
438
In addition, our results suggested that inherited defects in NK cells, APP and Wnt pathways were 439 positively selected in tumorigenesis and metastasis. Therefore, cancer patients are highly selected, and thus, it provides an explanation for the fact that only 12-20% of the heavy smokers develop lung cancer 441 in their lifetime, although 85% of the lung cancer patients are heavy smokers ( 58, 59 ). Cancer causally 442 environmental factors play an important role in tumorigenesis, however, without a susceptible germline 443 genome (i.e., genetic defects in NK cells, APP and Wnt pathways), they still cannot induce cancer. We 444 proposed that germline genome is the most important factor in determining if a person will get cancer 445 in one's lifetime, and cancer is the result of the interactions between high-risk germline genomes and 446 risk-factors (i.e., environmental factors and lifestyles). remained, for example, defected genes in NK cells were largely shared by different cancer types, 459 however, each cancer type has some unique NK cell gene defects. Given the fact that tissue/organ-460 resident NK cells are different and diverse ( 60 ), additional studies will be needed to elucidate if defected 461 genes are dominantly expressed in tissue/organ-resident NK cells. If so, adoptive transfer of tissue-462 resident NK cells could be considered to be more efficient in cancer prevention and TIL's recruitments. 463
NK cells share lots of expression programs with NKT cells, which is a subset of innate-like T cells. 464
Both NK cells and NKT cells are cytotoxic cells, which trigger innate immune responses, provide the 465 first level of defense against infected cells and tumor cells, produce cytokines and trigger immune 466 responses without a prior sensitization by the immune system. Along with this long, we suspected that 467 the inherited defects in NKT cells could also play similar roles which were discussed in this study, 468 although the cell number of the NK cells is nearly 200 times of the NKT cells. 469
470
Methods 471
Datasets 472
Based on the availability of the whole exome sequencing (WES) of germline gnomes, their paired 473 tumor genomes, and paired RNA-seq data, 14 common cancer types were selected from TCGA (n=200 474 at least for each cancer type). To remove the effects of virus-infection for the NK cell study, we 475 removed the virus-infected tumors. Only 15% of the liver tumors (i.e., this number is too small to 476 conduct analysis) without virus infection, thus, we excluded this cancer type for further analysis. Thus, 477 13 common cancers used in this study were BLCA, BRCA, COAD, LGG, HNSC, KIRC, LUAD, 478 LUSC, PRAD, SKCM, STAD, THCA, and UCEC. Because the primary melanoma samples were not 479 many, only metastatic SKCM samples were included for analysis. Distinct collected and identified as critical immune-related genes (the gene pool ). RNA-sequencing data of 507 melanoma patients in TCGA were used to screen the key genes. 508
509
Step#1 Initialize the candidate set of key genes, that is, 510
Step#2 Randomly select 30% genes fro m the gene set . 511
Step#3 Replace the features of elements in the patient set with to form the sample set . 512
Step#4 Group the samples by using the hierarchical clustering method. For each of the clustering, 513 clValid ( 63 ) was used to evaluate the clustering stability and the most stable clustering number was 514 recorded. 515
Step#5 Repeat Steps 2-4 100,000 times. Rank the most stable clustering numbers and select the most 516 suitable clustering number 3. 517
Step#6 Extract the genes when clustering number is 3, and rank the genes. Select the most informative 518 genes and record them as the final set of key-gene candidates (1,294 genes). 519
We used the 1,294 genes to conduct unsupervised clustering analyses of the RNA-seq data for each 520 cancer type to define TIME subtypes. 521
522

TIL abundance calculation and pathway enrichment analysis 523
A deconvolution approach ( 14 ) was used to extract the abundance of each immune cell based on their 524 gene markers from a tumor RNA-Seq data. Pathway enrichment analysis was conducted using DAVID 525 (https://david.ncifcrf.gov). 526 527
Assigning ICT trial samples into TIME subtypes 528
To assign an ICT-clinical trial sample into a TIME subtype, t-test statistics were first conducted in TIME-529 rich vs TIME-intermediate and TIME-intermediate vs TIME-poor tumors' RNA-seq data for the genes 530 derived from the NK cell-mediated cytotoxicity pathway and the Wnt signaling pathway. The 531 significantly differential genes (p<0.05) were used for conduct K-nearest neighbors (KNN, k=5) to assign 532 the sample to a TIME subtype. Spearman's rank correlation was conducted between the sample and the 533 
